Open access · CC-BY
via OpenAlex
MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program
Kimberly Lewis, BENJAMIN M. STROEBEL, Li Zhang, Bradley E. Aouizerat, Aras N. Mattis, Elena Flowers
International Journal of Molecular Sciences · 2024 · ▲ 23 citations
Abstract
The Diabetes Prevention Program (DPP) randomized controlled trial demonstrated that metformin treatment reduced progression to type 2 diabetes (T2D) by 31% compared to placebo in adults with prediabetes. Circulating micro-ribonucleic acids (miRs) are promising biomarkers of T2D risk, but little is known about their associations with metformin regimens for T2D risk reduction. We compared the change in 24 circulating miRs from baseline to 2 years in a subset from DPP metformin intervention (n = 50) and placebo (n = 50) groups using Wilcoxon signed rank tests. Spearman correlations were used to evaluate associations between miR change and baseline clinical characteristics. Multiple linear regression was used to adjust for covariates. The sample was 73% female, 17% Black, 13% Hispanic, and 50 ± 11 years. Participants were obese, normotensive, prediabetic, and dyslipidemic. Change in 12 miR levels from baseline to 2 years was significantly different in the metformin group compared with placebo after adjusting for multiple comparisons: six (let-7c-5p, miR-151a-3p, miR-17-5p, miR-20b-5p, miR-29b-3p, and miR-93-5p) were significantly upregulated and six (miR-130b-3p, miR-22-3p, miR-222-3p, miR-320a-3p, miR-320c, miR-92a-3p) were significantly downregulated in the metformin group. These miRs help to explain how metformin is linked to T2D risk reduction, which may lead to novel biomarkers, therapeutics, and precision health strategies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/ijms25115684
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Lewis, K., STROEBEL, B.M., Zhang, L., Aouizerat, B.E., Mattis, A.N., & Flowers, E. (2024). MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program. <em>International Journal of Molecular Sciences</em>. https://doi.org/10.3390/ijms25115684
Vancouver
Lewis K, STROEBEL BM, Zhang L, Aouizerat BE, Mattis AN, Flowers E. MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115684.
BibTeX
@article{kimberly2024MicroR,
title = {MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program},
author = {Kimberly Lewis and BENJAMIN M. STROEBEL and Li Zhang and Bradley E. Aouizerat and Aras N. Mattis and Elena Flowers},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115684},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Ophthalmology 2019
Open access · CC-BY
Association between Metformin and a Lower Risk of Age-Related Macular Degeneration in Patients with Type 2 Diabetes
The University of Texas Health Science Center at San Antonio 2019
Open access · US-GOV
Metformin and Vaccine Response in Older Adults
Diabetes Care 2009
Open access · CC-BY
Use of Multiple Metabolic and Genetic Markers to Improve the Prediction of Type 2 Diabetes: the EPIC-Potsdam Study
Research Square 2024
Preprint · CC-BY
MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 2018
Preprint · OA
Faculty Opinions recommendation of Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits.
PLoS ONE 2012
Open access · CC-BY